Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
Astegolimab, an anti-ST2 monoclonal antibody, significantly reduced moderate/severe exacerbations in COPD patients with frequent exacerbations in pooled ALIENTO and ARNASA analyses, showing promise for targeting the IL-33/ST2 pathway with g
Dupilumab significantly reduces emergency visits, hospital admissions, and systemic corticosteroid use in COPD patients with type 2 inflammation, offering a promising therapeutic option to mitigate exacerbation-associated morbidity.
This article explores disease stability as a key treatment target in COPD, analyzing major phase 3 trials that show stability predicts reduced exacerbations and mortality, supporting its use to guide therapy.
A recent MAIC study comparing mepolizumab and dupilumab in eosinophilic COPD patients found no significant difference between the treatments in reducing exacerbations or improving quality of life.
A recent study demonstrates that defining COPD exacerbation risk by any moderate or severe event over two years improves prediction accuracy and clinical decision-making compared to the standard one-year criteria.
A large UK cohort study reveals that beta-blockers reduce mortality in COPD patients with heart failure or ischemic heart disease, but concurrent long-acting beta-agonists may attenuate this benefit.
This study uses single-cell RNA sequencing of bronchoalveolar lavage cells to reveal immune dysregulation in COPD, highlighting profibrotic macrophages and monocytes as key players in airway remodeling and gas exchange impairment.
A single moderate COPD exacerbation markedly increases future exacerbation risk and long-term mortality, justifying its reclassification as high risk per GOLD 2026 guidelines and supporting refined risk stratification for better clinical ma
A nationwide cohort study found that SGLT2 inhibitor initiation was associated with a 27% lower risk of incident lung cancer in patients with COPD and type 2 diabetes compared with sulfonylureas.
Mosaic loss of Y chromosome (mLOY) in men is strongly associated with diminished lung function, increased emphysema severity, and faster epigenetic aging, positioning mLOY as a novel biomarker for respiratory aging and COPD risk in males.
A novel risk score incorporating COPD and graded renal dysfunction improves prediction of one-year mortality post-TAVI, showing excellent internal validity but requiring external validation before clinical use.
A novel conversation aid was developed and refined iteratively with patients and physicians to support shared decision-making for low carbon footprint inhaler prescribing in asthma and COPD, balancing environmental impact with safety and pa
This article reviews mepolizumab efficacy in COPD patients with variable blood eosinophil counts, showing benefits even with intermittent eosinophilia, expanding treatable phenotypes beyond persistent elevation.
CT-derived pulmonary vascular metrics, especially the small-artery to total arterial volume ratio, identify severe pulmonary hypertension in chronic lung disease, with distinct vascular remodeling patterns in COPD and fibrosing ILD.
A large pooled US cohort study found that COPD substantially reduces life expectancy, even among never-smokers, with years of life lost increasing progressively from GOLD stage 1 through stage 4.
Portable HEPA air cleaners plus motivational interviewing improved symptoms and quality of life in smokers with COPD by reducing indoor particulate matter, though lung function and exacerbations did not significantly change.
COPD exacerbations significantly increase cardiovascular risk for months. This article examines the link between COPD and heart disease, emphasizing proactive screening during flare-ups and evidence-based prevention strategies to improve su
Community-based COPD patients with mild or single moderate exacerbations show higher future exacerbation risks and lung structural abnormalities, despite stable lung function decline rates.
A large observational study finds that once-daily umeclidinium-vilanterol dry powder inhaler significantly reduces COPD exacerbation risk compared to glycopyrrolate-formoterol and tiotropium-olodaterol, while maintaining similar safety prof
A new clinical prediction model identifies prior recurrent falls, multimorbidity, and impaired dual-task mobility as key predictors of future falls in patients with COPD, offering a new tool for targeted geriatric intervention in respirator